Experimental evidence is rapidly emerging that the coupling of positive regulatory signals with the induction of negative feedback modulators is a mechanism of ®ne regulation in development. Studies in Drosophila and chick have shown that members of the SPROUTY family are inducible negative regulators of growth factors that act through tyrosine kinase receptors. We and others have shown that Fibroblast Growth Factor 10 (FGF10) is a key positive regulator of lung branching morphogenesis. Herein, we provide direct evidence that mSprouty2 is dynamically expressed in the peripheral endoderm in embryonic lung and is downregulated in the clefts between new branches at E12.5. We found that mSprouty2 was expressed in a domain restricted in time and space, adjacent to that of Fgf10 in the peripheral mesenchyme. By E14.5, Fgf10 expression was restricted to a narrow domain of mesenchyme along the extreme edges of the individual lung lobes, whereas mSprouty2 was most highly expressed in the subjacent epithelial terminal buds. FGF10 beads upregulated the expression of mSprouty2 in adjacent epithelium in embryonic lung explant culture. Lung cultures treated with exogenous FGF10 showed greater branching and higher levels of mSpry2 mRNA. Conversely, Fgf10 antisense oligonucleotides reduced branching and decreased mSpry2 mRNA levels. However, treatment with exogenous FGF10 or antisense Fgf10 did not change Shh and FgfR2 mRNA levels in the lungs. We investigated Sprouty2 function during lung development by two different but complementary approaches. The targeted overexpression of mSprouty2 in the peripheral lung epithelium in vivo, using the Surfactant Protein C promoter, resulted in a low level of branching, lung lobe edges abnormal in appearance and the inhibition of epithelial proliferation. Transient high-level overexpression of mSpry2 throughout the pulmonary epithelium by intra-tracheal adenovirus microinjection also resulted in a low level of branching. These results indicate for the ®rst time that mSPROUTY2 functions as a negative regulator of embryonic lung morphogenesis and growth. q
Introduction
Branching morphogenesis involves reiterated cycles of bud initiation, bud outgrowth and bud arrest. The mouse embryonic lung is an excellent model for studying the various phases of budding morphogenesis. Lung development starts at E9.5 with an outpocketing of the endoderm of the ventral foregut, termed the laryngotracheal groove, which rapidly gives rise to the trachea and the two main bronchi. These primary bronchi then undergo extensive branching in a predetermined pattern to give rise to four right lobes and a single left lobe in the mouse. Signi®cant progress has recently been made in elucidating the molecular and cellular basis of lung bud outgrowth and bud arrest. We have previously shown that Fibroblast Growth Factor 10 (FGF10), a member of the large Fibroblast Growth Factor family, is responsible for directed outgrowth of the lung endoderm (Bellusci et al., 1997b) . The spatially restricted expression of Fgf10 in the mesenchyme induces cell shape remodeling, cell migration and proliferation of the adjacent epithelial cells (Park et al., 1998; Weaver et al., 2000) . However, the most compelling evidence that FGF10 is involved in lung development is provided by the ®nding that Fgf10 null mutant mice develop no lung tissue distal to the trachea (Min et al., 1998; Sekine et al., 1999) . In addition, the targeted misexpression of dominant negative FgfR2b from the SP-C promoter and classical FgfR2b gene inactivation also abolish lung morphogenesis distal to the primary bronchi (Peters et al., 1994; Arman et al., 1999; De Moerlooze et al., 2000) .
Genetic and functional analysis of the complex cell±cell interactions involved in the formation of the tracheal system in the Drosophila embryo have shown that many key molecular mechanisms regulating branching are conserved between¯ies and mice. Tracheal placode morphogenesis is induced by Branchless (Bnl), an Fgf orthologue, which binds to and activates Breathless (Btl), which is an Fgf receptor orthologue (Glazer and Shilo, 1991; Sutherland et al., 1996) . Activation of the Btl tyrosine kinase receptor induces and directs the spatiotemporal orientation and morphology of primary, secondary and terminal tracheal branches. Sprouty (Spry) functions downstream from Btl as an inducible negative regulator, thereby limiting the number of branches formed (Hacohen et al., 1998) . The speci®c mechanisms by which Sprouty inhibits tracheal branching are unclear. Sprouty can also negatively regulate other tyrosine kinase receptors such as EgfR and Torso. Sprouty is an intracellular protein localized to cell membranes, possibly due to its C-terminal myristoylation site, which binds Gap-1 and Drk (a Grb-2 homologue), thereby inhibiting Ras activation (Casci et al., 1999) .
The mouse and human genomes contain four and three members of the Sprouty gene family, respectively (Hacohen et al., 1998; de Maximy et al., 1999; Minowada et al., 1999) . We have recently shown that blocking the function of mSpry2 using antisense oligonucleotides stimulates branching in embryonic mouse lungs in culture and increases epithelial proliferation and the expression of cytological differentiation markers . This strongly suggests that the FGF/FGFR/SPRY pathway is indeed functionally conserved between¯y and mouse. Further evidence for such functional conservation has recently been provided by Minowada et al. (1999) . These authors showed that Sprouty2 is induced by various members of the FGF family and that its overexpression in chick limb buds after retroviral infection causes a reduction in limb bud outgrowth consistent with a decrease in FGF signaling from the apical ectodermal ridge (Minowada et al., 1999) .
In this study, we aimed to determine the functional relationship between SPROUTY2 and the key regulator of branching morphogenesis, FGF10. We found that the expression of mSpry2 was restricted temporally and spatially to the distal tips of epithelial branches of embryonic mouse lung. It was downregulated in the clefts that form between the epithelial branches, whereas Fgf10 was expressed at adjacent sites in the peripheral mesenchyme. By implanting FGF-coated beads, we showed that epithelial mSpry2 expression was locally upregulated by FGF10 in embryonic lung cultures. We also used antisense oligodeoxynucleotides (ODNs) to abolish the expression of Fgf10; they reduced lung branching and decreased mSpry2 mRNA levels. We then designed two different but complementary gain of function experiments to investigate Sprouty2 function in lung development. We used a transgenic approach to misexpress mSpry2 in vivo under the control of the SP-C promoter. This resulted in a lower level of branching, lung lobe edges abnormal in appearance and inhibition of epithelial proliferation. Transient overexpression of mSpry2 in vitro throughout the pulmonary epithelium by intra-tracheal adenoviral microinjection also led to a lower level of branching. These results support the notion that the FGF10/FGFR2/mSPRY2 pathway is involved in the ®ne regulation of respiratory organogenesis.
Results

Expression of mSpry2 and Fgf10 in the embryonic mouse lung
Expression of mSpry2 was detected at the earliest stages of lung morphogenesis in the mouse (Fig. 1) . As the primary bronchial buds arise laterally from the laryngotracheal groove, which is located in the¯oor of the primitive pharynx at E10.5, mSpry2 expression was detected by wholemount in situ hybridization in the epithelium of the primary bronchial buds (Fig. 1A) . Weaker expression of mSpry2 expression was also detected in the mesenchyme surrounding the primitive trachea and in the stomach. Vibratome sections showed a low level of mSpry2 expression in the mesenchyme of distal lung buds (data not shown). Expression of mSpry2 rapidly became limited to the growing tips of the peripheral lung epithelium, although some low-level expression persisted in the mesenchyme. This highly restricted pattern of epithelial mSpry2 expression was then repeated in the secondary branching of lobar (right lung) and primary segmental bronchi (left lung) on E11/E11.5 (Fig. 1B,C) , and during the appearance of the tertiary segmental bronchial branches on E12.5 (Fig. 1D) .
We compared specimens at slightly different stages of development of the left upper segmental bronchus on E11 (Fig. 1E±G) , and found that mSpry2 was weakly expressed at the site of emergence of a nascent lateral bronchial bud and that the mSpry2 in situ hybridization signal at the bud tip increased in intensity as the bud began to elongate, and to move away from the parent bronchus. Expression of mSpry2 was found to be induced de novo, or at least upregulated from very low background levels, at sites at which a new monopodial, lateral bud would later arise (small black arrow). This temporal and spatial pattern of mSpry2 expression at the peripheral epithelial tips was repeated at every branching event, at least until E14.5 (Fig. 1J) . We investigated in more detail the temporal and spatial expression of mSpry2 during individual tip splitting events on E12.5 (Fig.  1H,I ). We found that mSpry2 expression at the tip of the individual epithelial bud increased to a peak just before bud outgrowth stopped and the tip split. The region of tissue in which mSpry2 was expressed then split laterally into two separate domains during the dichotomous budding event and expression was sharply downregulated in the cleft between the two daughter buds. The level of mSpry2 expression in the tip of each daughter bud was found to be low at the recommencement of the bud elongation cycle.
By E14.5, the mSpry2 signal was clearly detected in the peripheral zone of the lung, where dichotomous branching is most active, although a mSpry2 signal was also detected in branch tips deep within the lung, where ®ll-in branching also occurs (Fig. 1J,L) . We and others have previously shown that Fgf10 is expressed in lung mesenchyme adjacent to the tips of newly forming bronchial branches (Bellusci et al., 1997b; Park et al., 1998) . We show here that the spatial and temporal, mesenchymal±epithelial juxtaposition of Fgf10 and mSpry2 expression persists in the periphery of the lung to E14.5. Fgf10 gave a highly concentrated signal along the edge of each lung lobe (Fig. 1K,M) , a region of highly active peripheral airway morphogenesis and epithelial proliferation.
FGF10-coated beads upregulate mSpry2 spatial expression
The incubation time with the alkaline-phosphatase substrate was critical to evaluate a difference in endogenous Sprouty2 expression in the lung. A short incubation time (1 h) showed that endogenous levels of mSpry2 expression were not uniform throughout the lung epithelium after 24 h in culture ( Fig. 2A) . After 5 h of incubation, when the signal reached the saturation level, Sprouty2 expression appeared to be homogenous (data not shown). (Please note that Fig. 1D shows Sprouty2 expression in a E12.5 lung incubated for 5 h with the substrate.) In normal E12 lungs, mSpry2 was expressed in the rostral lobes of both lungs, but the level of expression was low in the caudal lobes ( Fig. 2A,C) . We therefore inserted heparin-sepharose beads coated with FGF10 into the lateral side of the caudal lobe and cultured the lungs for 24 h, to investigate the effects of FGF10 on the spatial expression of mSpry2, with a low background level of endogenous expression. In control E12 lung culture experiments ( Fig. 2A,C) , beads coated with BSA had no effect on the spatial pattern of mSpry2 expression in the lung epithelium. However, FGF10-coated beads strongly induced mSpry2 expression in adjacent epithelial tips of the caudal lobes (Fig. 2B,D) , in which the basal level of expression was low. In addition, epithelial tips close to the FGF10-coated beads grew to a larger size, as previously reported by ourselves and others (Bellusci et al., 1997b; Park et al., 1998) . The increase in Fig. 1 . Gene expression in the mouse embryonic lung. Expression in the mouse embryonic lung of Sprouty2 (A±G,J,L) and Fgf10 (K,M) was detected by whole-mount in situ hybridization, followed by vibratome sectioning. (A) Spry2 is expressed on E9.75±E10 in the distal buds. Note that the right bronchus has a larger expression domain than the left and that Spry2 expression is also detected in the mesenchyme around the developing stomach (st) and around the trachea (tr). (B) At E11, Spry2 expression is detected throughout the epithelium with a higher level in the distal buds. A signi®cant level of expression is also found in the proximal mesenchyme around the trachea and in the distal mesenchyme. (C,D) On E11.5 and E12.5, Spry2 expression is restricted to the distal epithelium. (E±G) High magni®cation of the left lobe on E11, E11.25 and E11.5 showing Spry2 expression increasing during bud outgrowth. Note that mSpry2 expression is induced de novo, or is at least upregulated from a very low background level of expression, at sites at which a new monopodial, lateral bud will arise (small black arrow). mSpry2 expression was particularly marked in these enlarged epithelial tips.
Exogenous FGF10 and the abolition of Fgf10 expression affect downstream effector genes
The linking of FGF10 to mSPRY2 as an inducible negative regulator was con®rmed by two independent but complementary approaches. First, whole lungs were treated with exogenous FGF10 and gene expression was quanti®ed by competitive RT-PCR. FGF10 (500 ng/ml; Fig. 2E ) gave a signi®cantly larger number of terminal branches than were observed in controls (65% increase, P , 0:05; Fig. 2F ). Furthermore, mSpry2, Bmp4 and SP-C expression levels were respectively 65, 57 and 54% higher than those in control lungs (Fig. 2G ). However, exogenous FGF10 had no effect on endogenous FgfR2 or Shh expression. Second, antisense ODNs against Fgf10 were designed to investigate the effect of reducing Fgf10 levels on the expression of downstream genes. E11.5 lungs treated for 4 days with antisense Fgf10 ODNs displayed signi®cantly lower levels of branching than the controls (Fig. 2E ). In the presence of 20 mM antisense Fgf10 ODN, the level of branching was 51% lower than that of lungs grown in either control medium or 20 mM sense or scrambled ODN (P , 0:05; Fig. 2F ). We used competitive antisense RT-PCR to investigate whether antisense Fgf10 decreased endogenous Fgf10 mRNA levels. Lungs cultured with antisense ODN had lower levels of Fgf10 mRNA than lungs cultured with scrambled and sense ODN. Densitometry showed that lungs cultured in the presence of 20 mM antisense Fgf10 ODN had 98% lower levels of Fgf10 mRNA (P , 0:05; Fig. 2G ). Not Terminal branches were counted and antisense ODN Fgf10 was found to cause a signi®cant decrease in branching, whereas exogenous FGF10 signi®cantly increased lung branching (P , 0:05). Error bars indicate the standard deviation. MC, media control; SE, sense ODN; AS, antisense ODN. (G) Effects of antisense Fgf10 ODN and exogenous FGF10 on downstream effector genes. Quanti®cation of competitive RT-PCR data by densitometric analysis, with normalization to b-actin. Antisense Fgf10 signi®cantly decreased endogenous Fgf10, mSpry2, Bmp4 and SP-C mRNA levels by 98, 94, 46 and 54%, respectively (P , 0:05). FGF10 (500 ng/ml) treatment gave mSpry2, Bmp4 and SP-C mRNA levels 65, 57 and 54% higher than those of the medium control (P , 0:05). No change in Shh and FgfR2 expression was observed. Values are expressed as the mean^SD with the medium control set at 100%. MC, medium control; SE, sense ODN; SR, scrambled ODN; AS, antisense ODN.
only did antisense Fgf10 ODN decrease Fgf10 mRNA levels, it also decreased the levels of mSpry2, Bmp4 and SP-C mRNA (94, 46 and 54% lower than scrambled oligonucleotide, sense oligonucleotide and medium controls, respectively, P , 0:05; Fig. 2G ). As for exogenous FGF10 application, no change was observed in FgfR2 and Shh mRNA levels.
Two independent but complementary gain of function experiments to evaluate the role of Sprouty2 during lung development
Our initial goal was to investigate the role of Sprouty2 during the early lung pseudoglandular stages (E9.5±E14.5). These early phases of development are highly suitable for analysis of the branching process. Branching can be followed with precision from E9.5 to E13.5 and in our experimental conditions whole-mount in situ hybridization could be performed up to E15.5. We used two different approaches to investigate Sprouty2 function during lung development. In the ®rst, we overexpressed Sprouty2 in vivo, using the SP-C promoter. In this protocol, transgene expression was initially low from E9.5 until E14.5 and drastically upregulated from E15.5 onwards (Wert et al., 1993) . This enabled us to analyze the effects of a modest increase in Sprouty2 mRNA levels in the distal lung epithelium during the early pseudoglandular stage (E9.5±E14.5). Particular attention was paid to potential defects in branching and lobe shape. Changes in gene expression may be dif®cult to assess due to low levels of transgene expression during the pseudoglandular stage. In addition, biological samples may be dif®cult to obtain in large quantities when dealing with embryonic lethal phenotypes. Therefore, in the second approach, recombinant adenovirus was used to trigger in vitro transient, but very strong, expression of Sprouty2 throughout the lung epithelium.
Gene expression in normal and transgenic lung
The SP-C promoter has been widely used to drive the expression of transgenes in the peripheral lung epithelium (for review see Warburton et al., 2000) . The SP-C promoterdriven expression of transgenes has been shown to accurately reproduce the pattern of endogenous SP-C gene expression (Wert et al., 1993) . To determine when and where we might expect overexpression of the SP-CmSpry2 transgene, we used whole-mount in situ hybridization to determine the pattern of endogenous SP-C gene expression. Endogenous SP-C expression levels were low between E10 and E13.5 and then increased signi®cantly from E14.5 onwards (Fig. 3A) . Consistent with previously published studies, endogenous SP-C expression was restricted to the distal airway epithelium. However, a novel feature of the expression pattern observed was the tendency for endogenous SP-C expression to be concentrated in the distal airway epithelium at the extreme lateral edges of all the lung lobes from E14.5 onwards (Fig. 3B,C) . This temporal and spatial pattern of upregulation of endogenous SP-C expression from E14.5 onwards proved to be critical for evaluation of the transgenic lung phenotype.
We also evaluated SP-C-mSpry2 transgene expression using whole-mount in situ hybridization to compare the mSpry2 signal in wild-type and transgenic lungs. We found that mSpry2 was overexpressed in the peripheral lung epithelium on E14.5, showing a pattern of expression similar to the wild-type pattern of endogenous SP-C expression (Fig. 3D±F) . Thus, the transgene was overexpressed in the expected domain of the peripheral epithelium. Sonic hedgehog and Bmp4 were expressed at similar levels in transgenic and normal lungs (Fig. 3G±I and data not shown).
2.6. Targeted overexpression of mSprouty2 in peripheral lung epithelium using the SP-C promoter results in a lower level of branching, lung lobe edges abnormal in appearance and inhibition of epithelial proliferation Thirteen SPC-Spry2 transgenic embryos were obtained at various stages of development. Sprouty2 overexpression was not detected in nine transgenic lungs of normal phenotype, suggesting that the expression cassette was integrated into a silent part of the genome. However, four embryos displayed an abnormal lung phenotype (two on E14.5, one on E16.5 and one on E18.5). An example of Sprouty2 overexpression at E14.5 is illustrated in Fig. 3D±F . The transgenic embryos exhibiting developmental defects in the lung were similar in stage and wet weight to the control embryos of the corresponding litter (for details see Section 4). Clear macroscopic differences were observed at each stage analyzed. Lungs from SP-C-mSpry2 transgenic embryos were signi®cantly smaller than wild-type embryos (Figs. 4 and 5) and differed in shape. Primary lobe formation in the lungs was not affected, but each of the lobes was substantially smaller in volume than its counterpart in the wildtype, as re¯ected in wet weight. The wet weight of the lungs normalized to the wet weight of the embryos con®rmed this result and excluded general growth retardation (0.100 and 0.101 for the transgenic embryos on E16.5 and E18.5, respectively, vs. 0.230^0.047 and 0.211^0.050 for the corresponding normal embryos on E16.5 and E18.5, respectively).
Another particularly striking feature of the transgenic phenotype was the`moth-eaten', dysplastic appearance of the edges of the lobes, which was evident on E14.5 (compare Fig. 4G±J and K±N) , but even more marked on E16.5 (Fig. 5A±F ). This phenotype is of particular interest given the distinct spatial juxtaposition of endogenous SP-C, Fgf10 and mSpry2 expression along the edges of each of the lobes of wild-type lungs.
Another feature of interest was that the terminal buds were less tightly packed and appeared to have undergone substantially less complex tip splitting than wild-type specimens. This is clearly shown in Fig. 3G±I , in which Sonic hedgehog was used to label the epithelium. In contrast, in E16.5 and E18.5 specimens, transgenic whole-mount lungs were more opaque to transillumination than wild-type lungs, in which ®nely branched¯uid-®lled terminal buds were easily visible (Fig. 5G±L) .
The histological appearance of SP-C-mSpry2 transgenic lungs was also extremely abnormal (Fig. 6) . The most obvious feature was the appearance of multiple deep pleural clefts (Fig. 6D,H ) at sites at which interlobular septa had clearly failed to adhere. Such clefts are never seen in normal lung, in which the interlobular septa form within the lung parenchyma as very thin ®broelastic structures, resulting in a completely smooth pleural surface. Several non-mutually exclusive explanations can be proposed for these defects. First, abnormal deposition of elastin ®bers, which are known to be important in the architecture of the lung, may signi®cantly alter the pleural surface. However, after staining with orcein (a speci®c stain for elastin ®bers), no significant difference in elastin deposition was observed between transgenic and normal lungs on E16.5 and E18.5 (data not shown). Alternatively, these pleural defects may be linked to differences in the expression of Fgf9, a gene expressed in lung mesothelium from very early stages of lung development (Colvin et al., 1999) . In situ hybridization was performed with sections of lung taken on E14.5, E16.5 and E18.5 and no signi®cant difference in Fgf9 expression was observed between transgenic and control lungs (data not shown). Histological analysis showed no abnormalities in the proximal±distal patterning of the lung epithelium in SP-C-Spry2 lungs on E14.5 and E16.5. In control and transgenic lungs, the bronchiolar proximal epithelium was columnar, whereas the distal respiratory epithelium was low cuboidal (Fig. 6A±D) . We also used immunohistochemistry (staining for a-smooth muscle actin) to investigate mesenchymal differentiation. Changes in the expression of the a-smooth muscle actin gene have been reported in transgenic lungs displaying defects in proximal±distal differen- tiation (Weaver et al., 1999) . In transgenic and wild-type lungs, a-smooth muscle actin was detected in a thin layer of cells surrounding the proximal bronchioles, but was absent from distal tubules (data not shown), suggesting that mesenchyme differentiation was normal in transgenic lungs. The peripheral airways of SP-C-mSpry2 transgenic lungs on E16.5 and E18.5 were also collapsed, resulting in a histological picture in which peripheral,¯uid-®lled airways were much less evident than in the controls. We investigated potential defects in¯uid pumping by in situ hybridization of sections to analyze CFTR expression between E14.5 and E18.5. CFTR is a major chloride channel present in epithelial cells in a large variety of organs including lung and intestinal tract (Snouwaert et al., 1992) . Its distribution in transgenic lungs at the various stages considered appeared to be normal (data not shown). However, the mesenchyme appeared to be much thicker in transgenic than in normal lungs (Fig. 6K,L) . The large airways were also closer to the pleural surface in the transgenic lungs than in the controls, indicating a major defect in morphogenesis of the ®nely divided peripheral air spaces underlying the pleural edge.
Effect of Sprouty2 overexpression on epithelial and mesenchymal cell proliferation
The abnormal phenotype of SP-C-Spry2 transgenic lungs suggests that Sprouty2 overexpression results in lower levels of cell proliferation, particularly in the epithelial component of the lung. We therefore investigated cell proliferation by PCNA analysis of E14.5 normal and transgenic lungs. The proportion of cells containing the PCNA protein was determined. There was about 50% less cell proliferation in the epithelium of the transgenic lung than in the control (12 vs. 26%, respectively; Fig. 7) . The rate of cell proliferation in the mesenchyme was not signi®cantly different in transgenic and control lungs (6 vs. 7%, respectively), suggesting a speci®c effect of SPROUTY2 on the epithelium.
Overexpression of mSpry2 in vitro reduces branching and decreases endogenous Bmp4 and SP-C mRNA levels
We could not conclude from the results obtained with SPC-Spry2 transgenic lungs that SPROUTY2 directly inhibited FGF10 activity. The expression of Bmp4, a downstream FGF10 target gene, was not signi®cantly altered in transgenic lungs, as shown by whole-mount in situ hybridization. We investigated in more detail the effects of Sprouty2 overexpression on branching and gene expression by intratracheal microinjection of an adenovirus containing the mSpry2 cDNA (AdmSpry2). Lungs were cultured for 4 days and harvested. RNA was extracted from the lungs and used for competitive RT-PCR. The level of mSpry2 mRNA was signi®cantly higher in adenovirus-injected cultures than in medium controls and control virus-injected cultures. Densitometry showed that mSpry2 mRNA levels were 23 times higher in lungs intra-tracheally microinjected with AdmSpry2 than in controls (Fig. 8B) . We also used Western blotting with anti-HA antibody to assess the overproduction of exogenous mSPRY2 protein. Western blotting of protein from AdmSpry2-microinjected lungs with an anti-HA antibody demonstrated that the mSpry2 transgene was indeed overexpressed and the corresponding protein overproduced, with the protein not detected in medium controls or AdGFP-infected samples (Fig. 8C) . Immunohistochemical staining showed that adenovirus-mediated gene transfer resulted in epithelium-speci®c transgene expression in embryonic lungs (data not shown). The distribution of the mSPRY2 protein, the product of the transgene, was determined using anti-HA antibody. Staining for the protein was found in lung epithelial cells, whereas no staining was detected in control virus-injected and medium control lung tissues. Thus, we had established a reliable method for overexpressing mSpry2 in embryonic lung explants.
We then assessed the effects of intra-tracheal microinjection of AdmSpry2 on lung branching morphogenesis. Overexpression of mSpry2 signi®cantly inhibited lung branching (Fig. 9A) , with 53% less branching observed than with the control green¯uorescent protein (GFP) adenovirus vector or with medium control cultures (P , 0:05, data not shown). We investigated whether mSPRY2 regulated downstream effector genes in the FGF pathway by extracting RNA from adenovirus-microinjected lungs and using it for competitive RT-PCR and gel electrophoresis. Densitometry showed that microinjection of AdmSpry2 resulted in a modest but signi®cant (P , 0:05) decrease in Bmp4 and SP-C mRNA levels (46 and 51% lower than those in medium controls and control virus-injected cultures, respectively; Fig. 9B ). However, microinjection of AdmSpry2 did not affect FgfR2 and Shh mRNA levels.
Discussion
Early embryonic lung development depends on a delicate balance between excitatory and inhibitory factors. In this study, we demonstrate a novel set of feedback loop linking FGF10 and SPRY2 during lung branching morphogenesis. We provide for the ®rst time a description of the dynamic expression of Sprouty2 in the distal epithelium during mouse embryonic lung development and show that Fgf10 is expressed at adjacent sites in the peripheral mesenchyme. In lung culture explants, FGF10 was shown by in situ hybridization and competitive RT-PCR to increase mSpry2 gene expression. Conversely, using antisense ODN strategies, we found that abolishing expression of Fgf10 reduced lung branching and greatly decreased mSpry2 mRNA levels. We also report that in vivo overexpression of Sprouty2 in the distal lung epithelium, using the SP-C promoter, leads to a lower level of branching associated with a lower level of epithelial cell proliferation. However, no signi®cant change in Bmp4 expression levels was observed by whole-mount in situ hybridization. A similar reduction in branching was observed if Sprouty2 was overexpressed in vitro in the lung epithelium after infection with a recombinant adenovirus. We analyzed gene expression by competitive RT-PCR and found a speci®c decrease in the level of expression of Bmp4 and SP-C, whereas the level of expression of Shh and FgfR2 was not changed. We therefore suggest that mSPRY2 plays an inhibitory role, balancing the stimulatory effects of FGF10 in the developing lung.
3.1. Expression of Sprouty2 during lung development mSpry2 was expressed from the very early stages of bud formation during lung development and its expression increased as the bud grew, peaking at the start of the bud Fig. 8 . Overexpression of mSpry2 in embryonic lung explants. Competitive RT-PCR was carried out with total RNA from cultured embryonic lungs to determine mSpry2 mRNA levels. (A) Gel electrophoresis showing signi®cantly higher mSpry2 mRNA levels in lungs injected with AdmSpry2 than in medium and AdGFP virus controls. (B) mSpry2 overexpression was quanti®ed by densitometry of the electrophoretic bands in`(A)'. Intra-tracheal microinjection of mSpry2 adenovirus resulted in mSpry2 mRNA levels signi®cantly (P , 0:05) higher than those in medium and GFP virus controls. Error bars indicate the standard deviation. (C) Overexpression of mSPRY2 was also quanti®ed by Western blot analysis in cultured lungs. Immunoreactivity for the HA-epitope was only detected in AdmSpry2-infected lungs, and not in medium (MC) or AdGFP-infected controls. arrest phase. Weak mSpry2 expression was also observed in the lung mesenchyme on E10.5. A similar pattern of expression has been reported in the progress zone of the limb and in the mesenchyme of the maxillary and mandibular processes (Minowada et al., 1999 and data not shown). However, in the lung, the expression of mSpry2 was very rapidly restricted to the distal lung epithelium (by E11.5) in a domain adjacent to that in which Fgf10 was expressed in the distal mesenchyme. Fgf10 expression at late pseudoglandular stages (from E13.5 to E15.5) was particularly evident at the edges of each lobe. This suggests that in addition to its role in directing bud outgrowth, FGF10 is also involved in peripheral morphogenesis in each lobe. On E14.5, mSpry2 was located mainly in the distal/lateral epithelium of each lobe but was also detected at low levels on the sides of the lobes. This spatial and temporal pattern of expression of ligand and negative regulator at adjacent sites suggests that one regulates the other, as in the¯y tracheal system.
FGF10 is the major regulator of early mSpry2 expression
The induction of Sprouty2 by FGF members has been reported in other systems. In Drosophila, sprouty is induced by Branchless, a Fgf-like ligand (Hacohen et al., 1998) . In the chick embryo, Sprouty2 can be induced in the interlimb region by beads coated with FGF2, FGF4 or FGF8 beads (Minowada et al., 1999) . However, we show here that FGF10 is a key regulator of inducible Sprouty2 expression in the early stages of embryonic lung development. Expression of mSpry2 in the epithelium was locally upregulated by FGF10-coated beads in our organ explant culture assay. This upregulation was con®rmed by competitive RT-PCR. Exogenous FGF10 also induced Bmp4, a gene known to be downstream from FGF10 (Lebeche et al., 1999) . The expression of Shh and FgfR2 was not affected. These results con®rm a previous report showing that FGF10 does not regulate Shh expression (Lebeche et al., 1999) and provide positive controls for this study.
As Fgf10 null mutant embryos develop no lung tissue distal to the trachea (Min et al., 1998; Sekine et al., 1999) , we used an antisense ODN strategy to abolish Fgf10 expression and to determine more precisely the effects of this inhibition on lung branching morphogenesis and the expression of downstream effector genes. The abolition of Fgf10 expression decreased the number of terminal branches and reduced mSpry2 mRNA levels considerably (by 94%) and Bmp4 and SP-C mRNA levels more moderately (by 46 and 54%, respectively). Two conclusions can be drawn. First, FGF10 is not the only regulator of Bmp4 expression, as Bmp4 RNA levels were only moderately reduced (compared to Sprouty2 levels) when Fgf10 expression was inhibited. This is important as Bmp4 is a critical patterning gene reported to act downstream from FGF10 in the lung system. Compensatory mechanisms may therefore maintain Bmp4 expression despite a decrease in FGF10 activity. The second important conclusion is that Sprouty2 expression depends speci®cally on FGF10 activity at these early stages. However, it is likely that other growth factors acting through tyrosine kinase receptors expressed later on in lung development are also regulating Sprouty2 expression. It is still unclear whether FGF10 acts directly or indirectly on the endoderm to induce mSpry2 expression. FGF10 may also regulate the synthesis of other growth factors involved in maintaining Sprouty2 expression. A recent report showed that mouse Fgf9 is expressed in the lung mesothelium from very early stages of lung development (Colvin et al., 1999) . However, FGF9 is very unlikely to act directly on the endoderm to induce Sprouty2 as it has a very low af®nity for FGFR2b, the major FGF receptor in the epithelium at that stage (Ornitz et al., 1996) . Fgf10 is the only Fgf family member to date found to be dynamically expressed in association with bud formation (Bellusci et al., 1997b) and this suggests that from very early stages of lung development until E14.5, FGF10 is probably the main regulator of mSpry2 expression. Fig. 9 . Overexpression of mSpry2 by adenovirus microinjection inhibits lung branching morphogenesis and decreases Bmp4 and SP-C mRNA levels. (A) Intra-tracheal microinjection of mSpry2 adenovirus gave a lower level of lung branching than medium controls or lungs injected with AdGFP control virus. (B) Total RNA was extracted from cultured embryonic lung explants and Bmp4, SP-C, Shh and FgfR2 mRNA levels were determined by competitive RT-PCR and gel electrophoresis. Densitometric analysis of the electrophoresis bands was performed. AdmSpry2-microinjected lungs showed moderately but signi®cantly (P , 0:05) lower levels of Bmp4 and SP-C mRNA than medium control and control virusinjected lungs. No difference was observed in FgfR2 and Shh mRNA levels. Values are expressed as the mean^SD with the medium control set at 100%.
3.3. We suggest that Sprouty2, expressed in the epithelium in response to FGF10, tightly regulates bud outgrowth during the early stages and terminal lobe morphogenesis at later stages of lung development
We investigated Sprouty2 function during lung development by performing two different but complementary gain of function experiments. In the ®rst approach, transgenic mice designed to misexpress mSpry2 in the peripheral embryonic lung epithelium under control of the SP-C promoter displayed a consistent hypoplastic lung phenotype observed on E14.5, when both endogenous SP-C and the transgene begin to be expressed at high levels, and persisting until E18. The salient features of this hypoplastic/ dysplastic lung phenotype include a lack of fusion of interlobular septa, low levels of peripheral epithelial proliferation, and low levels of¯uid in¯ation of potential respiratory tubules, with all these features most marked around the extreme edges of all the lung lobes. Epithelial and mesenchymal differentiation and CFTR expression appeared to be normal. Thus, SPROUTY2 seems to act mainly as a negative regulator of epithelial cell proliferation.
Failure to fuse of interlobular septae
The interlobular septae are inconspicuous ®broelastic structures present in wild-type embryonic mouse lung. The failure of these structures to fuse is an obvious feature of SP-C-directed mSpry2 transgene overexpression, resulting in the`moth-eaten', excessively lobulated appearance of transgenic lungs. Fibroelastic dysplasia is also a prominent feature of the postnatal hypoalveolar lung phenotype of Fgfr3/Fgfr4 double null mutant mice (Weinstein et al., 1998) , suggesting that FGF signaling must be crucial for ®broelastic matrix homeostasis throughout wild-type lung morphogenesis. Differences in Fgf9 expression in the mesothelium (Colvin et al., 1999) may account for the observed defects. However, no difference in Fgf9 expression was detected between wild-type and transgenic lungs. In addition, elastin ®bers, which are thought to provide mechanical support during septation, were produced normally in the transgenic lung. Additional growth factors and extracellular matrix components may be altered in the transgenic lungs and this possibility will be studied in future investigations.
Epithelial tubule collapse
In the embryonic lung, net¯uid ef¯ux is driven by active chloride secretion (Zhou et al., 1996) . As hydraulic pressure has long been suspected to play a key role in controlling fetal lung growth (Souza et al., 1995a,b) , the apparent lack of peripheral lung liquid may also play an important role in the hypoplastic/dysplastic lung phenotype. However, CFTR expression was normal in transgenic lungs, suggesting that the apparent lack of¯uid ®lling in the epithelial tubules may result from the inhibition of other¯uid secretion mechanisms.
SPROUTY2 inhibits epithelial cell proliferation
The functional expression of Sprouty2 was con®rmed by whole-mount in situ hybridization on E14.5 in the same temporal and spatial site at which the endogenous SP-C promoter was ®rst activated at high levels of transcription. This was associated with marked decreases in epithelial proliferation indices at E14.5, suggesting that the overexpression of mSpry2 strongly inhibits signals promoting the growth of the wild-type epithelium. The proliferation of mesenchyme cells was not affected in the transgenic lung. We also found that the expression of Sonic hedgehog, a gene encoding a major lung mesenchyme proliferation factor (Bellusci et al., 1997a) , did not appear to be affected in lungs overexpressing Sprouty2 in vivo and in vitro. These results suggest that the effects of SPROUTY2 are limited to the lung epithelium and are relatively speci®c to the FGF10 pathway. Consistent with these results, a recent report showed that FGF10 does not control Shh expression in the epithelium (Lebeche et al., 1999) . Previous reports have also shown that sprouty overexpression in Drosophila inhibits several tyrosine kinase receptor signaling pathways, including Fgf and Egf receptor pathways. In addition, Sprouty2 overexpression in the chick limb after retroviral infection causes a reduction in limb bud outgrowth consistent with reduced FGF signaling from the apical ectodermal ridge (Kramer et al., 1999; Minowada et al., 1999; Reich et al., 1999) .
Despite the evidence reported herein, we were unable to show conclusively that SPROUTY2 directly inhibited FGF10 activity. In particular, we observed no effect on the expression of Bmp4, a previously reported downstream target gene of FGF10, in transgenic lungs. We then overexpressed Sprouty2 in vitro by intra-tracheal injection of recombinant mSpry2 adenovirus. We found that mSpry2 adenovirus not only decreased lung branching, thereby con®rming the results obtained with the transgenic approach, but also decreased Bmp4 and SP-C but not Shh or FgfR2 RNA levels. The decrease in Bmp4 expression was modest given the high level of Sprouty2 expression. However, we ruled out non-speci®c downregulation of gene expression due to the adenovirus itself because the GFP-recombinant control adenovirus did not alter gene expression. In addition, AdmSpry2 infection did not change Shh and FgfR2 mRNA levels, suggesting that the observed downregulation of Bmp4 is speci®c. Taken together, our results suggest that SPROUTY2-independent pathways also regulate Bmp4 expression and that growth factors other than FGF10 regulate Bmp4 mRNA levels. Our results also suggest that FGF10 may regulate Bmp4 during the early pseudoglandular stage but not later in development.
In conclusion, we have provided evidence that FGF10 plays a key role in inducing and maintaining Sprouty2 expression in the epithelium of embryonic mouse lung at early stages of development. The results presented herein also show that SPROUTY2 acts as a negative modulator of embryonic lung morphogenesis and growth.
Experimental procedures
Whole lung culture
Lung explants removed on day 11.5 (E11.5) of gestation were placed on Nucleopore ®lters, which were then laid on the surface of 500 ml F12 DMEM medium containing 50 units/mg penicillin and streptomycin and 0.1% heat-inactivated fetal calf serum in Nunclon dishes (technique adapted from Lebeche et al., 1999) . We investigated the local effects of FGF10 on these cultures by implanting heparin beads (Sigma) impregnated with human recombinant FGF-10 (100 mg/ml) in the distal lung and incubating for 24 h. BSA-impregnated beads, incubated in the lung for the same length of time, were used as a control.
For culture with antisense oligonucleotides, E11.5 lungs were removed from embryos by microdissection and placed in sterile Hank's balanced salt solution. The lungs were then placed on MF-Millipore ®lter disks (0.80 mm pores, Millipore, Bedford, MA). The disks were then placed on stainless steel wire mesh and cultured at the air±medium interface in chemically de®ned medium: BGJb (GIBCO, Grand Island, NY) with 0.1 mg/ml ascorbic acid and 50 units/ml penicillin and streptomycin. Lungs were incubated in 5% CO 2 /95% air at 378C for 4 days, with the medium changed every 2 days.
Exogenous FGF10 treatment
Exogenous recombinant human FGF10 (Research and Development) was added to cultured E11.5 lung explants. The following concentrations of FGF10 were used: 50, 250 and 500 ng/ml. Explants were cultured for 4 days with the medium changed every 2 days.
In situ hybridization
Microdissected and cultured lungs were ®xed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 2 h. They were washed twice with PBS, dehydrated overnight in 70% ethanol at 48C and stored in absolute ethanol. The whole-mount in situ hybridization protocol used was based on a previously described method (Winnier et al., 1995) . Samples were usually incubated for 5 h at 378C with the alkaline-phosphatase substrate. Lungs cultured in vitro with the BSA or FGF10 beads were incubated for only 1 h at 378C. The following mouse cDNAs were used as templates for the synthesis of digoxigenin-labeled riboprobes: a 948 bp full-length mouse Spry2 cDNA , a 758 bp mouse SP-C cDNA, a 584 bp Fgf10 cDNA (Bellusci et al., 1997b) 
